United States· US:0002-4815_01706851-8b56-40b8-9e22-e454b3e24f95
Verzenio
A abemaciclib product containing abemaciclib, registered in United States by Eli Lilly and Company. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Abemaciclib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EF03 (abemaciclib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Abemaciclib · ATC L01EF03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abemaciclib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abemaciclib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$181.14
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ABEMACICLIB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- L01EF03
- ATC class
- Abemaciclib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 19, 2026
Packs & prices · 4
- ndc1100024815541 BLISTER PACK in 1 CARTON (0002-4815-54) / 14 TABLET in 1 BLISTER PACK
- ndc1100024815622 BLISTER PACK in 1 CARTON (0002-4815-62) / 14 TABLET in 1 BLISTER PACK
- ndc110002-4815-54
- ndc110002-4815-62
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
224 interactions on record for abemaciclib.
Graded by severity as the source publishes them — 71 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abemaciclib · interactions on record
224 records
- 71 severe
- 153 moderate
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abemaciclib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomVerzenios 100mg tabletsEli Lilly and Company Ltd
- CanadaVERZENIOELI LILLY CANADA INC
- CzechiaVERZENIOSEli Lilly Nederland B.V., Utrecht
- SpainVERZENIOS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAEli Lilly Nederland B.V.
- SwitzerlandVerzenios 100 mg, comprimés filmésEli Lilly (Suisse) SA
- FranceVERZENIOS 100 mg, comprimé pelliculéELI LILLY NEDERLAND BV (PAY-BAS)
- BelgiumVerzenios 100 mgEli Lilly Nederland
- IrelandVerzenios 100 mg Film-coated tabletEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Verzenios
- Liechtenstein · Verzenios
- Norway · Verzenios
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1a7e959-5175-4136-a446-79d17af3eb86 GET /v1/drugs/f1a7e959-5175-4136-a446-79d17af3eb86?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "ABEMACICLIB",
"productndc": "0002-4815",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA208716",
"marketing_category": "NDA"
}See everything about abemaciclib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.